ArticleEMBO molecular medicine2026
KCNA2 variants cause dilated cardiomyopathy, obesity and sleep apnea through RAC-ERK pathway.
Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dilated cardiomyopathy (DCM) is a heart condition characterized by systolic and diastolic dysfunction. In many instances, patients with DCM coexist with obesity and sleep apnea. It is unclear whether genetic variants contribute to the combined phenotypes of DCM, obesity, and sleep apnea. Here, using next-generation sequencing, we identified pathogenic KCNA2 variants in patients of diverse ancestry with DCM, Obesity, and Sleep Apnea (termed DOSA). Electrophysiological and biochemical assays using biosensors revealed loss of membrane current due to trafficking defects in cells expressing KCNA2 variants. Furthermore, cellular models including patient-specific iPSC cardiomyocytes and organoid models displayed RAC1-ERK1/2 hyperactivation in disease pathogenesis. A Drosophila model expressing KCNA2 variant showed DOSA-like phenotypes which was rescued using RAC1 inhibitors. Our results provide the first evidence that KCNA2 variants can lead to DOSA phenotypes, further expanding the genetic regulatory roles of potassium channels in human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.